1. Home
  2. CVE Database
  3. CVE-2022-30277
MEDIUM · 5.7

CVE-2022-30277

BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, in...

Vulnerability Description

BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, including electronic protected health information (ePHI), protected health information (PHI) and personally identifiable information (PII).

CVSS Score

5.7

MEDIUM

CVSS:3.1/AV:P/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
Attack Vector
PHYSICAL
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
REQUIRED
Scope
UNCHANGED
Confidentiality
HIGH
Integrity
HIGH
Availability
NONE

Affected Products

VendorProductVersions
BdSynapsys4.20

Related Weaknesses (CWE)

CWE-613

References

FAQ

What is CVE-2022-30277?

CVE-2022-30277 is a vulnerability with a CVSS score of 5.7 (MEDIUM). BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, in...

How severe is CVE-2022-30277?

CVE-2022-30277 has been rated MEDIUM with a CVSS base score of 5.7/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2022-30277?

Check the references section above for vendor advisories and patch information. Affected products include: Bd Synapsys.